ANDA 209223, held by Teva Pharms USA. Deferasirox.
As of Nov 15, 2026, ANDA 209223 (Deferasirox), held by Teva Pharms USA, was first approved by FDA on Apr 24, 2020, with 0 approved supplements and 0 published complete response letters.
| Apr 24, 2020 | Original application | Approved | |
| Nov 25, 2019 | Original application | Approved |
| Deferasirox90MG · tablet;oral | Deferasirox | Discontinued |
| Deferasirox360MG · tablet;oral | Deferasirox | Discontinued |
| Deferasirox180MG · tablet;oral | Deferasirox | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
